Generic Cafcit Availability

Cafcit is a brand name of caffeine, approved by the FDA in the following formulation(s):

CAFCIT (caffeine citrate - solution;intravenous)

  • Manufacturer: BEDFORD LABS
    Approval date: September 21, 1999
    Strength(s): EQ 30MG BASE/3ML (EQ 10MG BASE/ML) [RLD] [AP]

CAFCIT (caffeine citrate - solution;oral)

  • Manufacturer: BEDFORD LABS
    Approval date: April 12, 2000
    Strength(s): EQ 30MG BASE/3ML (EQ 10MG BASE/ML) [RLD] [AA]

Has a generic version of Cafcit been approved?

Yes. The following products are equivalent to Cafcit:

caffeine citrate solution;intravenous

  • Manufacturer: EXELA PHARMA SCIENCE
    Approval date: September 21, 2006
    Strength(s): EQ 30MG BASE/3ML (EQ 10MG BASE/ML) [AP]
  • Manufacturer: FRESENIUS KABI USA
    Approval date: July 20, 2007
    Strength(s): EQ 30MG BASE/3ML (EQ 10MG BASE/ML) [AP]
  • Manufacturer: LUITPOLD
    Approval date: May 15, 2007
    Strength(s): EQ 30MG BASE/3ML (EQ 10MG BASE/ML) [AP]
  • Manufacturer: SAGENT PHARMS
    Approval date: August 29, 2012
    Strength(s): EQ 30MG BASE/3ML (EQ 10MG BASE/ML) [AP]
  • Manufacturer: SUN PHARMA GLOBAL
    Approval date: September 30, 2009
    Strength(s): EQ 30MG BASE/3ML (EQ 10MG BASE/ML) [AP]

caffeine citrate solution;oral

  • Manufacturer: EXELA PHARMA SCS LLC
    Approval date: September 21, 2006
    Strength(s): EQ 30MG BASE/3ML (EQ 10MG BASE/ML) [AA]
  • Manufacturer: FRESENIUS KABI USA
    Approval date: January 31, 2008
    Strength(s): EQ 30MG BASE/3ML (EQ 10MG BASE/ML) [AA]
  • Manufacturer: LUITPOLD
    Approval date: November 20, 2009
    Strength(s): EQ 30MG BASE/3ML (EQ 10MG BASE/ML) [AA]
  • Manufacturer: SAGENT PHARMS
    Approval date: August 29, 2012
    Strength(s): EQ 30MG BASE/3ML (EQ 10MG BASE/ML) [AA]
  • Manufacturer: SUN PHARMA GLOBAL
    Approval date: September 30, 2009
    Strength(s): EQ 30MG BASE/3ML (EQ 10MG BASE/ML) [AA]

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Cafcit. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

There are no current U.S. patents associated with Cafcit.

Glossary

TermDefinition
Drug PatentA drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation.
Drug ExclusivityExclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant.
RLDA Reference Listed Drug (RLD) is an approved drug product to which new generic versions are compared to show that they are bioequivalent. A drug company seeking approval to market a generic equivalent must refer to the Reference Listed Drug in its Abbreviated New Drug Application (ANDA). By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart.
AAProducts in conventional dosage forms not presenting bioequivalence problems. Products coded as AA contain active ingredients and dosage forms that are not regarded as presenting either actual or potential bioequivalence problems or drug quality or standards issues. However, all oral dosage forms must, nonetheless, meet an appropriate in vitro bioequivalence standard that is acceptable to the Agency in order to be approved.
APInjectable aqueous solutions and, in certain instances, intravenous non-aqueous solutions. It should be noted that even though injectable (parenteral) products under a specific listing may be evaluated as therapeutically equivalent, there may be important differences among the products in the general category, Injectable; Injection. For example, some injectable products that are rated therapeutically equivalent are labeled for different routes of administration. In addition, some products evaluated as therapeutically equivalent may have different preservatives or no preservatives at all. Injectable products available as dry powders for reconstitution, concentrated sterile solutions for dilution, or sterile solutions ready for injection are pharmaceutical alternative drug products. They are not rated as therapeutically equivalent (AP) to each other even if these pharmaceutical alternative drug products are designed to produce the same concentration prior to injection and are similarly labeled. Consistent with accepted professional practice, it is the responsibility of the prescriber, dispenser, or individual administering the product to be familiar with a product's labeling to assure that it is given only by the route(s) of administration stated in the labeling.
Hide
(web5)